2DE0 Stock Overview A clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. More details
Risk Analysis + 2 more risks
See All Risk Checks {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Capture your thoughts, links and company narrative
Genprex, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Genprex Historical stock prices Current Share Price US$6.50 52 Week High US$37.82 52 Week Low US$6.50 Beta -0.63 1 Month Change 0% 3 Month Change -15.93% 1 Year Change -76.93% 3 Year Change -94.75% 5 Year Change -89.44% Change since IPO -98.60%
Recent News & Updates
Genprex, Inc. Announces First Patient Has Been Enrolled and Dosed in the Phase 2 Expansion Portion of the Company’S Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy Jan 24
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer Dec 16
Genprex, Inc. Receives Notice from Nasdaq Regarding Non-Compliance with Stockholders' Equity Requirement Nov 20
Genprex, Inc. Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa Gene Therapy in Combination with Tecentriq in Extensive Stage Small Cell Lung Cancer Oct 15
Genprex Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement Sep 28 Genprex, Inc. Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer See more updates
Genprex, Inc. Announces First Patient Has Been Enrolled and Dosed in the Phase 2 Expansion Portion of the Company’S Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy Jan 24
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer Dec 16
Genprex, Inc. Receives Notice from Nasdaq Regarding Non-Compliance with Stockholders' Equity Requirement Nov 20
Genprex, Inc. Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa Gene Therapy in Combination with Tecentriq in Extensive Stage Small Cell Lung Cancer Oct 15
Genprex Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement Sep 28 Genprex, Inc. Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa Immunogene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer Genprex, Inc Announces Executive Changes
Genprex, Inc., Annual General Meeting, Jun 18, 2024 May 01 Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer Genprex, Inc. has completed a Follow-on Equity Offering. Mar 26
Genprex, Inc. has filed a Follow-on Equity Offering. Mar 21
Genprex, Inc. has filed a Follow-on Equity Offering. Mar 20
Genprex, Inc. Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers Mar 12
Genprex, Inc. Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators Feb 07
Genprex, Inc. Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer Feb 05
New major risk - Market cap size Feb 03
No longer forecast to breakeven Jan 23
Genprex, Inc. to Present Data on the Use of Reqorsa for the Treatment of Lung Cancers At 2023 Aacr-Nci-Eortc International Conference on Molecular Targets and Cancer Therapeutics Oct 05
Genprex Receives Non-Compliance Notice From Nasdaq Sep 02
Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs Aug 23
Genprex, Inc. announced delayed 10-Q filing Aug 17
Genprex, Inc. Receives Fast Track Designation from the FDA for Its Small Cell Lung Cancer Drug Candidate Jul 12
Genprex, Inc. Grants Chinese Patent for REQORSA(R) Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers Jul 06
Genprex Receives U.S. FDA Fast Track Designation for REQORSA Immunogene Therapy in Combination with Tecentriq for the Treatment of Small Cell Lung Cancer Jun 29
Genprex, Inc. Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA(R) in Combination with Tagrisso(R) in Advanced Non-Small Cell Lung Cancer May 31
Genprex, Inc. Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating Reqorsa Immunogene Therapy in Non-Small Cell Lung Cancer May 26 Genprex, Inc. announced delayed 10-Q filing May 17
No longer forecast to breakeven Apr 02
High number of new directors Mar 24
High number of new and inexperienced directors Feb 17
Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA(R) in Combination with Tagrisso(R) in Advanced Non-Small Cell Lung Cancer Dec 15
High number of new and inexperienced directors Dec 13
High number of new and inexperienced directors Nov 21
Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer Aug 16
High number of new and inexperienced directors Apr 28
Genprex, Inc. Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancercer Apr 01
Genprex, Inc. Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA Immunogene Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer Mar 04
Genprex, Inc. Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA Immunogene Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer Mar 03
Genprex, Inc. Announces Positive Preclinical Data for Use of Genprex’s ONCOPREX® Nanoparticle Delivery System for Delivery of FAS DNA Plasmid to Treat Metastatic Colorectal Cancer Jan 28
Genprex, Inc. to Accelerate Opening of Acclaim-1 Clinical Trial Sites Jan 12
Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer Jan 06
Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer Jan 05 Genprex, Inc.(NasdaqCM:GNPX) dropped from Russell 3000E Index
Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review Jun 24
Forecast to breakeven in 2024 Jun 11
Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer May 06
Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer May 05
Genprex, Inc. Announces Formation of Clinical Advisory Board Feb 09
Genprex, Inc. Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer Jan 14
Genprex, Inc. Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer Dec 23
Genprex, Inc Completes Manufacturing Technology Transfer for Novel Gene Therapy Dec 10
Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer Dec 03
Genprex, Inc. Appoints George K. Gittes to Its Scientific Advisory Board Nov 11
Genprex, Inc. Promotes Eric Chapdelaine to Vice President of Manufacturing Oct 27
Genprex, Inc. Names Thomas C. Gallagher, Esq. as Senior Vice President of Intellectual Property and Licensing Sep 22 Shareholder Returns 2DE0 DE Biotechs DE Market 7D 0% 1.2% 2.3% 1Y -76.9% -5.6% 16.7%
See full shareholder returns
Return vs Market: 2DE0 underperformed the German Market which returned 2% over the past year.
Price Volatility Is 2DE0's price volatile compared to industry and market? 2DE0 volatility 2DE0 Average Weekly Movement n/a Biotechs Industry Average Movement 5.7% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.5%
Stable Share Price: 2DE0's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 2DE0's volatility change over the past year.
About the Company Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes.
Show more Genprex, Inc. Fundamentals Summary How do Genprex's earnings and revenue compare to its market cap? 2DE0 fundamental statistics Market cap €4.08m Earnings (TTM ) -€28.78m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2DE0 income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$30.86m Earnings -US$30.86m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/04/30 22:02 End of Day Share Price 2024/02/01 00:00 Earnings 2023/12/31 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Genprex, Inc. is covered by 1 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Molloy Alliance Global Partners
